Work

Sa41 Real-world Front-line Use of Enfortumab Vedotin - Pembrolizumab (ev+p) After Adjuvant Nivolumab in Advanced Urothelial Cancer(auc)

Year: 2026

Type: conference-abstract

Source: Value in Health

DOI: 10.1016/j.jval.2026.03.2209

Authors: Melanie Mayer, Aram Babcock, Blanca Homet Moreno, Chethan Ramamurthy, Haojie Li, Ronac Mamtani, Nicholas Seewald

Institutions: University of Pennsylvania, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W7166052637

Cites:

Cited by:

Related to: 10